[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Travere Therapeutics director Timothy Coughlin reported an option exercise combined with a share sale. He exercised stock options for 10,000 shares of common stock at an exercise price of $26.52 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $50.0747 per share.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance. Following these transactions, Coughlin directly holds 56,250 shares of Travere Therapeutics common stock.

Insights

Equity compensation and insider-trading analyst

Pre-planned, routine option exercise and sale with modest scale.

Director Timothy Coughlin exercised options for 10,000 shares at an exercise price of $26.52 and sold 10,000 shares at a weighted average of $50.0747. This is a classic exercise-and-sell pattern where derivative compensation is converted into cash.

The sale occurred under a written Rule 10b5-1 trading plan adopted on November 19, 2025, signaling the timing was pre-scheduled rather than opportunistic. After these trades, he still directly owns 56,250 shares, indicating a remaining equity stake.

From an investor perspective, such pre-planned transactions are typically viewed as routine liquidity events rather than strong signals about the company’s prospects. The filing does not show remaining derivative positions, suggesting this specific option grant has been fully exercised.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($500,747)

Net Sell 3 txns

Insider Coughlin Timothy

Role null

Sold 10,000 shs ($501K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$26.52	$265K
Sale	Common Stock	10,000	$50.0747	$501K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 66,250 shares (Direct, null)

Footnotes (1)

1. This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable.

Key Figures

Shares sold: 10,000 shares Sale price (weighted average): $50.0747 per share Options exercised: 10,000 shares +5 more

8 metrics

Shares sold 10,000 shares Open-market sale of common stock on June 12, 2026

Sale price (weighted average) $50.0747 per share Common stock sale price range between $50.00 and $50.32

Options exercised 10,000 shares Stock option exercise on June 12, 2026

Option exercise price $26.52 per share Conversion or exercise price of stock option

Shares held after transaction 56,250 shares Direct common stock ownership following transactions

Derivative position remaining 0 options Stock option balance after full 10,000-share exercise

10b5-1 plan adoption date November 19, 2025 Date written trading plan meeting Rule 10b5-1(c) was adopted

Option expiration date May 8, 2028 Expiration date of the exercised stock option grant

Key Terms

Rule 10b5-1(c), weighted average sale price, Stock Option (Right to Buy), derivative security, +1 more

5 terms

Rule 10b5-1(c) regulatory

"written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $50.0747"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) ... underlying security title Common Stock"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 04:47 PM Accepted by SEC EDGAR 06/16/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coughlin Timothy

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		M		10,000	A	$26.52	66,250	D
Common Stock	06/12/2026		S(1)		10,000	D	$50.0747(2)	56,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.52	06/12/2026		M			10,000	(3)	05/08/2028	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)